Intra-abdominal anaerobic infections: Bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents

Clinical Infectious Diseases

Volumn 35, Issue SUPPL. 1, 2002, Pages

  Goldstein, Ellie J C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; DESFLUOROQUINOLONE; ERTAPENEM; GARENOXACIN; GEMIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ANAEROBIC INFECTION; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL VIRULENCE; BACTERIOLOGY; BACTERIUM ISOLATION; CONFERENCE PAPER; HUMAN; INTESTINE FLORA; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL;

ABDOMINAL ABSCESS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTEREMIA; BACTERIA, ANAEROBIC; BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; BETA-LACTAMS; CARBAPENEMS; CLINICAL TRIALS; FLUOROQUINOLONES; HUMANS; INDOLES; LACTAMS; NAPHTHYRIDINES; QUINOLINES; QUINOLONES;

EID: 0036060637     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/341930     Document Type: Conference Paper

References (50)

1. Current practices of perioperative bowel preparation among North American colorectal surgeons
2. A review: Lessons from an animal model of intra-abdominal sepsis
3. Animal model system for studying virulence of host response to Bacteroides fragilis
4. Nonperforative appendicitis: A continuing surgical dilemma
5. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime against recent community-acquired isolates of the Bacteroides fragilis group
6. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections
7. The bacteriology of gangrenous and perforated appendicitis - Revisited
8. Bacterial studies of peritoneal cavity and postoperative surgical wound drainage following perforated appendix in children
9. Gangrenous and perforated appendicitis with peritonitis: Treatment and bacteriology
10. Bilophila wadsworthia isolates from clinical specimens
11. A microbiological comparison between acute and complicated appendicitis
12. Has misdiagnosis of appendicitis decreased over time? A population based analysis
13. Anaerobic bacteremia
14. Anaerobic bacterial bacteremia: 12-Year experience in two military hospitals
15. Attributable mortality of bacteremia associated with Bacteroides fragilis group
16. Occurrence of Bacteroides fragilis enterotoxin gene carrying strains in Germany and the United States
17. Association of enterotoxogenic Bacteroides fragilis with bacteremia
18. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species
19. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: Findings of a multicenter observational trial
20. United States hospital survey of anaerobic culture and susceptibility methods II
21. Evaluation of the epsilometer (E-Test) for susceptibility testing of anaerobic bacteria
22. Emergence of antibiotic-resistant bacteria in cases of peritonitis after abdominal surgery affects the efficacy of empirical antimicrobial therapy
23. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections
24. Meropenem versus imipenem in the treatment of intra-abdominal infections
25. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections
26. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990-1994
27. National survey on the susceptibility of Bacteroides fragilis group: Report and analysis of trends for 1997-2000
28. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: A 4-year study
29. Susceptibility of anaerobic flora recovered from complicated intra-abdominal infections to clinafloxacin and imipenem
30. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections
31. In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains
32. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers
33. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections
34. Activity of CP-99219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin-tazobactam against 489 anaerobes
35. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria
36. Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobe agents
37. Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intra-abdominal infection
38. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscess caused by Bacteroides fragilis and Escherichia coli
39. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model
40. Serum bactericidal activity of trovafloxacin against selected anaerobic pathogens
41. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes
42. Comparison of the antibacterial activities of the quinolone Bay 12-8039, gatifloxacin, (AM-1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin
43. Comparative in vitro activity of Bay 12-8039 and five other antimicrobial agents against anaerobic bacteria
44. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria
45. In vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens
46. Gemifloxacin (SB 26805) compared to other oral antimicrobials agents against unusual anaerobes
47. In vitro activity of gemifloxacin (SB 26805) against anaerobes
48. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS 284756
49. Comparative antianerobic activity of BMS 284756